中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

72 records (took 0.036 seconds)

    Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
    41.
    发明授权
    Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems 有权
    制备α-2激动剂聚合物药物递送系统的水包油法

    公开(公告)号：US07589057B2

    公开(公告)日：2009-09-15

    申请号：US11395019

    申请日：2006-03-31

    Applicant: James Chang ,  Patrick Hughes

    Inventor： James Chang ,  Patrick Hughes

    IPC: A61K31/27 ,  A61K31/535

    CPC classification number: A61K31/4166

    Abstract: Biocompatible microparticles include an ophthalmically active alpha-2 adrenergic receptor agonist and a biodegradable polymer. The microparticles include oil-in-water emulsified microparticles which can be used to treat an ocular condition, such as glaucoma.

    Abstract translation: 生物相容性微粒包括眼科活性α-2肾上腺素能受体激动剂和可生物降解的聚合物。 微粒包括可用于治疗眼部疾病如青光眼的水包油乳化微粒。

    Therapeutic Lacrimal Canalicular Inserts And Related Methods
    42.
    发明申请
    Therapeutic Lacrimal Canalicular Inserts And Related Methods 审中-公开
    治疗性泪腺插管及相关方法

    公开(公告)号：US20080038317A1

    公开(公告)日：2008-02-14

    申请号：US11572097

    申请日：2005-09-07

    Applicant: Chin-Ming Chang ,  Rhett Schiffman ,  James Chang ,  R. Jordan

    Inventor： Chin-Ming Chang ,  Rhett Schiffman ,  James Chang ,  R. Jordan

    IPC: A61F2/14 ,  A61K38/12 ,  A61P27/00

    CPC classification number: A61K9/0051 ,  A61F9/00772

    Abstract: Lacrimal canalicular inserts include a polymeric component and a therapeutic component. The therapeutic component is released from the inserts for extended periods of time, such as for more than about 2 weeks after placement in a lacrimal canaliculus of an individual. The polymeric component may include one or more non-biodegradable polymers, one or more biodegradable polymers, or combinations thereof. The therapeutic component may include one or more therapeutic agents. Therapeutically effective amounts of the therapeutic component are released from the insert and provide sustained drug delivery to the eye and/or the nasolacrimal system of the individual.

    Abstract translation: 泪小管插入物包括聚合物组分和治疗组分。 治疗组分从插入物中延长的时间段释放，例如放置在个体的泪小管中超过约2周。 聚合物组分可以包括一种或多种不可生物降解的聚合物，一种或多种可生物降解的聚合物，或其组合。 治疗组分可以包括一种或多种治疗剂。 治疗成分的治疗有效量从插入物释放并提供持续的药物递送到个体的眼睛和/或鼻泪管系统。

    LOW IMMUNOGENICITY CORTICOSTEROID COMPOSITIONS
    43.
    发明申请
    LOW IMMUNOGENICITY CORTICOSTEROID COMPOSITIONS 审中-公开
    低免疫球蛋白组合物

    公开(公告)号：US20070224278A1

    公开(公告)日：2007-09-27

    申请号：US11741366

    申请日：2007-04-27

    Applicant: Robert Lyons ,  Michael Robinson ,  James Chang ,  Sam Lam ,  John Trogden ,  Scott Whitcup

    Inventor： Robert Lyons ,  Michael Robinson ,  James Chang ,  Sam Lam ,  John Trogden ,  Scott Whitcup

    IPC: A61K9/14 ,  A61K31/56

    CPC classification number: A61K9/0019 ,  A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/715 ,  A61K47/02 ,  A61K47/34 ,  A61K47/36 ,  A61K47/40

    Abstract: Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes or into a joint are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps t a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

    Abstract translation: 提供了曲安奈德组合物，以及使用这种组合物的方法，其可用于注射到人眼玻璃体或关节中。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中，在25℃下，粘度为约140,000cps至约280,000cps，剪切速率为0.1 /秒。组合物有利地将曲安奈德颗粒悬浮较长时间。

    Ophthalmic visualization compositions and methods of using same
    44.
    发明申请
    Ophthalmic visualization compositions and methods of using same 审中-公开
    眼科可视化组合物及其使用方法

    公开(公告)号：US20070218007A1

    公开(公告)日：2007-09-20

    申请号：US11378506

    申请日：2006-03-17

    Applicant: James Chang ,  Robert Lyons

    Inventor： James Chang ,  Robert Lyons

    IPC: A61K49/00

    CPC classification number: A61K9/10 ,  A61K9/0048 ,  A61K9/107 ,  A61K47/26 ,  A61K47/38 ,  A61K47/44 ,  A61K49/0041 ,  A61K49/0043 ,  A61K49/0071

    Abstract: Compositions and methods useful for at least assisting in visualizing vitreous bodies of eyes of humans or animals are provided. Such compositions include a contrast component and a carrier component and are substantially free of any therapeutic agent effective to have pharmacological activity in an eye in which the composition is placed. Methods of using such compositions as visualization devices are also provided.

    Abstract translation: 提供了用于至少辅助人类或动物的眼睛的玻璃体视觉化的组合物和方法。 这样的组合物包括造影剂组分和载体组分，并且基本上没有任何有效地在其中放置组合物的眼睛中具有药理活性的治疗剂。 还提供了使用这些组合物作为可视化装置的方法。

    Cyclosporin compositions
    47.
    发明申请
    Cyclosporin compositions 审中-公开
    环孢菌素组合物

    公开(公告)号：US20070015691A1

    公开(公告)日：2007-01-18

    申请号：US11181409

    申请日：2005-07-13

    Applicant: James Chang ,  Orest Olejnik ,  Bruce Firestone

    Inventor： James Chang ,  Orest Olejnik ,  Bruce Firestone

    IPC: A61K38/13 ,  A61K36/47

    CPC classification number: A61K38/13 ,  A61K9/0048 ,  A61K9/107 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44

    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives , phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof.

    Abstract translation: 本文公开了一种组合物，其包含约0.001％至约0.4％的环孢菌素A，蓖麻油和选自醇乙氧基化物，醇，烷基糖苷，烷基多糖苷，烷基酚乙氧基化物，氧化胺，嵌段聚合物，羧化的 醇或烷基酚乙氧基化物，羧酸/脂肪酸，纤维素衍生物，乙氧基化醇，乙氧基化烷基酚，乙氧基化芳基酚，乙氧基化脂肪酸，乙氧基化脂肪酸，乙氧基化脂肪酯和油，脂肪醇，脂肪酯，二醇酯，羊毛脂基 衍生物，卵磷脂和卵磷脂衍生物，木质素和木质素衍生物，甲酯，单酸甘油酯和衍生物，磷脂，聚丙烯酸，聚乙二醇，聚环氧乙烷 - 聚氧丙烯共聚物，聚环氧乙烷，聚合物表面活性剂，聚环氧丙烷，丙氧基化醇，丙氧基化烷基酚， 丙氧基化脂肪酸，基于蛋白质的冲浪 助剂，肌氨酸衍生物，硅氧烷基表面活性剂，脱水山梨糖醇衍生物，硬脂酸盐，蔗糖和葡萄糖酯及其衍生物及其组合。

Patent Agency Ranking